Alumis (NASDAQ:ALMS) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Alumis (NASDAQ:ALMS) in a research report report published on Monday morning, Benzinga reports.

A number of other analysts also recently weighed in on ALMS. Guggenheim started coverage on shares of Alumis in a research report on Tuesday, July 23rd. They set a buy rating and a $32.00 price target for the company. SVB Leerink initiated coverage on shares of Alumis in a research report on Tuesday, July 23rd. They set an outperform rating and a $29.00 price target on the stock. Leerink Partnrs raised Alumis to a strong-buy rating in a report on Tuesday, July 23rd. Finally, Morgan Stanley started coverage on Alumis in a report on Tuesday, July 23rd. They set an overweight rating and a $36.00 target price on the stock. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $27.50.

Alumis Price Performance

Shares of ALMS opened at $13.00 on Monday. Alumis has a one year low of $10.45 and a one year high of $13.53.

Institutional Investors Weigh In On Alumis

Large investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new position in Alumis during the second quarter worth about $3,376,000. Towerview LLC acquired a new position in shares of Alumis in the 2nd quarter worth approximately $4,123,000. Ally Bridge Group NY LLC bought a new stake in shares of Alumis in the 2nd quarter worth approximately $8,229,000. Yu Fan bought a new stake in Alumis during the second quarter worth approximately $10,502,000. Finally, SR One Capital Management LP acquired a new position in Alumis in the second quarter worth approximately $26,067,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.